Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors.

Levy, Benjamin P

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors. [electronic resource] - Oncology (Williston Park, N.Y.) Jul 2016 - 601-12 p. digital

Publication Type: Journal Article; Review

0890-9091


Adenocarcinoma--drug therapy
Antineoplastic Agents--therapeutic use
Biomarkers, Tumor--genetics
Disease Progression
Drug Resistance, Neoplasm--drug effects
ErbB Receptors--genetics
Humans
Lung Neoplasms--drug therapy
Mutation
Neoplasm Staging
Protein Kinase Inhibitors--therapeutic use
Protein-Tyrosine Kinases--antagonists & inhibitors
Quality of Life
Randomized Controlled Trials as Topic
Treatment Outcome